Comparing Clementia Pharmaceuticals (CMTA) and Millendo Therapeutics (MLND)

Clementia Pharmaceuticals (NASDAQ:CMTA) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Clementia Pharmaceuticals and Millendo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clementia Pharmaceuticals 0 4 2 0 2.33
Millendo Therapeutics 0 0 3 0 3.00

Clementia Pharmaceuticals presently has a consensus price target of $24.20, suggesting a potential downside of 8.61%. Millendo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 56.25%. Given Millendo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Millendo Therapeutics is more favorable than Clementia Pharmaceuticals.

Risk and Volatility

Clementia Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500.

Profitability

This table compares Clementia Pharmaceuticals and Millendo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clementia Pharmaceuticals N/A -44.73% -41.66%
Millendo Therapeutics -10,128.37% -41.84% -37.48%

Insider and Institutional Ownership

78.7% of Clementia Pharmaceuticals shares are held by institutional investors. Comparatively, 43.8% of Millendo Therapeutics shares are held by institutional investors. 7.4% of Millendo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Clementia Pharmaceuticals and Millendo Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clementia Pharmaceuticals N/A N/A -$58.13 million ($7.93) -3.34
Millendo Therapeutics $290,000.00 737.10 -$27.19 million ($17.58) -0.91

Millendo Therapeutics has higher revenue and earnings than Clementia Pharmaceuticals. Clementia Pharmaceuticals is trading at a lower price-to-earnings ratio than Millendo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Millendo Therapeutics beats Clementia Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.